Clinical trial
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic…
NCT00036868 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00036868 |
|---|---|
| Title | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer |
| Official title | A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, CMF regimen, cyclophosphamide, fluorouracil, methotrexate |
| Enrollment | 90 |
| Start date | Feb 1, 2002 |
| Primary completion | Jun 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 8, 2024 |
| Countries | Belgium, Denmark, Egypt, France, Netherlands, Poland, Serbia, South Africa, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: